On ECHEMI
Home > Drugs > Aspirin effervescent tablets

Aspirin effervescent tablets

Function and Efficacy

The main active ingredient of this drug is acetylsalicylic acid (aspirin), which has antipyretic, analgesic, anti-inflammatory, anti-rheumatic and platelet aggregation inhibitory effects.

Ingredients

The main ingredient of this product is aspirin. Its chemical name is 2-(acetoxy)benzoic acid. Molecular formula: C9H8O4; molecular weight: 180.16

Name Description Content CAS NO. Manufacturer
Acetylsalicylic acidIngredients

Antipyretic, analgesic, anti-inflammatory, anti-rheumatic and platelet aggregation inhibitor

More
50-78-2 35

Appearance

This product is white tablets.

Indication

It is used to treat fever caused by the common cold or influenza, and is also used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea.

Usage and Dosage

Dissolve in warm water and take orally. Children aged 6 to 14 years old, take 0.5 tablets at a time; children aged 14 years and above and adults, take 1 tablet at a time; if fever or pain persists, repeat the medication once every 4 to 6 hours, and do not exceed 4 times in 24 hours.

Adverse Reactions

Long-term and high-dose use may cause gastrointestinal reactions.

Precautions

1. Active ulcer disease or gastrointestinal bleeding caused by other reasons; 2. Hemophilia or thrombocytopenia; 3. People with a history of allergy to aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, angioedema or shock; It is forbidden for infants under 43 months old.

Special Population Medication

Precautions for children: Pediatric patients, especially those with fever and dehydration, are prone to toxic reactions. Acute febrile diseases, especially influenza and chickenpox, may be associated with Reye's syndrome when using this product. Severe cases may be fatal, which is rare in China. Precautions for pregnancy and lactation: Avoid use as much as possible. (1) This product easily crosses the placenta. Animal experiments have shown that the use of this product in the first three months of pregnancy can cause teratogenesis, such as spina bifida, skull cleft, facial cleft, leg deformity, and incomplete development of the central nervous system, internal organs and bones. There are also reports of fetal defects in humans after using this product. In addition, long-term and large-scale use of this product in the last three months of pregnancy can prolong the pregnancy period and increase the risk of post-term labor syndrome and antepartum hemorrhage. Use in the last two weeks of pregnancy can increase the risk of fetal hemorrhage or neonatal hemorrhage. Long-term use of the drug in the late pregnancy may also cause constriction or early closure of the fetal ductus arteriosus, leading to persistent pulmonary hypertension and heart failure in the newborn. It has been reported that excessive use or abuse of this drug in late pregnancy has increased the incidence of stillbirth or neonatal death (possibly due to ductus arteriosus occlusion, antepartum hemorrhage or low body weight). However, the above adverse reactions have not been found when using general therapeutic doses. (2) This product can be excreted in breast milk. When lactating women take 650 mg orally, the drug concentration in breast milk can reach 173-483 μg/ml after 5-8 hours. Therefore, long-term high-dose use may cause adverse reactions in infants. Precautions for the elderly: Elderly patients are prone to toxic reactions due to decreased renal function when taking this product, so the dose should be reduced.

Drug Interactions

1. This product should not be used together with anticoagulants (such as coumarin, heparin) and thrombolytic drugs (streptokinase); 2. Antacids such as sodium bicarbonate can increase the excretion of this product in the urine and reduce the blood concentration, so they should not be used together; 3. This product can increase gastrointestinal adverse reactions when used together with glucocorticoids (such as dexamethasone); 4. This product can enhance the effects of oral hypoglycemic drugs and methotrexate and should not be used together; 5. Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

Storage

Sealed, store in a dry place.

Packaging Specification

0.5g

Validity Period

24 months

Manufacturer

AstraZeneca Pharmaceutical Co., Ltd.

  • Founded in:

    1993-10-26
  • Address:

    No. 2 Huangshan Road, New District, Wuxi
  • Tax NO.:

    91320214607915071G
  • Registered Funds:

    $191.2 million
  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.